Phase ii prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy

A. Santoro, A. Comandone, U. Basso, H. Soto Parra, R. De Sanctis, E. Stroppa, I. Marcon, L. Giordano, F. R. Lutman, A. Boglione, A. Bertuzzi

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Introduction: We investigated the activity and safety of sorafenib, a multitargeted tyrosine-kinase inhibitor, in patients with advanced soft tissue sarcomas (STS). Patients and methods: An open-label nonrandomised multicentre phase II study was conducted in advanced STS patients pre-treated with anthracycline-based chemotherapy. Patients received sorafenib 400 mg twice daily for 28 days. The primary end point was the progression-free survival (PFS) rate at 6 months. Toxicity was assessed. Clinical outcomes were evaluated in all histologies and in leiomyosarcoma (L) and angiovascular sarcomas (A). Results: Between November 2006 and January 2010, 101 patients (36 L, 19 A, and 46 others) were enrolled; 76 patients per-protocol (PP) and 100 per intention-to-treat (ITT) were assessable for the primary end point. In the PP analysis, 11 (14.5) achieved partial response and 25 (32.9) stable disease; 6-month PFS rates were all histologies, 34.5; L, 38.4; and A, 56.3. In the ITT analysis, 6-month PFS results were 27.1, 35, and 35.5 in all histologies, L, and A, respectively. When stratified by histology, we observed a better PFS favouring leiomyosarcoma versus other histologies (P 0.033). Treatment was well tolerated. Conclusions: Sorafenib appears to be a promising option in leiomyosarcoma patients. This finding warrants further evaluation in histology-driven trials.

Original languageEnglish
Article numbermds607
Pages (from-to)1093-1098
Number of pages6
JournalAnnals of Oncology
Volume24
Issue number4
DOIs
Publication statusPublished - Apr 2013

Fingerprint

Anthracyclines
Sarcoma
Histology
Prospective Studies
Disease-Free Survival
Leiomyosarcoma
Therapeutics
Survival Rate
Intention to Treat Analysis
sorafenib
Protein-Tyrosine Kinases
Safety
Drug Therapy

Keywords

  • Angiosarcoma
  • Leiomyosarcoma
  • Soft tissue sarcoma
  • Sorafenib
  • Vascular sarcoma

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Phase ii prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy. / Santoro, A.; Comandone, A.; Basso, U.; Soto Parra, H.; De Sanctis, R.; Stroppa, E.; Marcon, I.; Giordano, L.; Lutman, F. R.; Boglione, A.; Bertuzzi, A.

In: Annals of Oncology, Vol. 24, No. 4, mds607, 04.2013, p. 1093-1098.

Research output: Contribution to journalArticle

Santoro, A. ; Comandone, A. ; Basso, U. ; Soto Parra, H. ; De Sanctis, R. ; Stroppa, E. ; Marcon, I. ; Giordano, L. ; Lutman, F. R. ; Boglione, A. ; Bertuzzi, A. / Phase ii prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy. In: Annals of Oncology. 2013 ; Vol. 24, No. 4. pp. 1093-1098.
@article{a7d3ac349bec47319f1aa4517f5579f0,
title = "Phase ii prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy",
abstract = "Introduction: We investigated the activity and safety of sorafenib, a multitargeted tyrosine-kinase inhibitor, in patients with advanced soft tissue sarcomas (STS). Patients and methods: An open-label nonrandomised multicentre phase II study was conducted in advanced STS patients pre-treated with anthracycline-based chemotherapy. Patients received sorafenib 400 mg twice daily for 28 days. The primary end point was the progression-free survival (PFS) rate at 6 months. Toxicity was assessed. Clinical outcomes were evaluated in all histologies and in leiomyosarcoma (L) and angiovascular sarcomas (A). Results: Between November 2006 and January 2010, 101 patients (36 L, 19 A, and 46 others) were enrolled; 76 patients per-protocol (PP) and 100 per intention-to-treat (ITT) were assessable for the primary end point. In the PP analysis, 11 (14.5) achieved partial response and 25 (32.9) stable disease; 6-month PFS rates were all histologies, 34.5; L, 38.4; and A, 56.3. In the ITT analysis, 6-month PFS results were 27.1, 35, and 35.5 in all histologies, L, and A, respectively. When stratified by histology, we observed a better PFS favouring leiomyosarcoma versus other histologies (P 0.033). Treatment was well tolerated. Conclusions: Sorafenib appears to be a promising option in leiomyosarcoma patients. This finding warrants further evaluation in histology-driven trials.",
keywords = "Angiosarcoma, Leiomyosarcoma, Soft tissue sarcoma, Sorafenib, Vascular sarcoma",
author = "A. Santoro and A. Comandone and U. Basso and {Soto Parra}, H. and {De Sanctis}, R. and E. Stroppa and I. Marcon and L. Giordano and Lutman, {F. R.} and A. Boglione and A. Bertuzzi",
year = "2013",
month = "4",
doi = "10.1093/annonc/mds607",
language = "English",
volume = "24",
pages = "1093--1098",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "4",

}

TY - JOUR

T1 - Phase ii prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy

AU - Santoro, A.

AU - Comandone, A.

AU - Basso, U.

AU - Soto Parra, H.

AU - De Sanctis, R.

AU - Stroppa, E.

AU - Marcon, I.

AU - Giordano, L.

AU - Lutman, F. R.

AU - Boglione, A.

AU - Bertuzzi, A.

PY - 2013/4

Y1 - 2013/4

N2 - Introduction: We investigated the activity and safety of sorafenib, a multitargeted tyrosine-kinase inhibitor, in patients with advanced soft tissue sarcomas (STS). Patients and methods: An open-label nonrandomised multicentre phase II study was conducted in advanced STS patients pre-treated with anthracycline-based chemotherapy. Patients received sorafenib 400 mg twice daily for 28 days. The primary end point was the progression-free survival (PFS) rate at 6 months. Toxicity was assessed. Clinical outcomes were evaluated in all histologies and in leiomyosarcoma (L) and angiovascular sarcomas (A). Results: Between November 2006 and January 2010, 101 patients (36 L, 19 A, and 46 others) were enrolled; 76 patients per-protocol (PP) and 100 per intention-to-treat (ITT) were assessable for the primary end point. In the PP analysis, 11 (14.5) achieved partial response and 25 (32.9) stable disease; 6-month PFS rates were all histologies, 34.5; L, 38.4; and A, 56.3. In the ITT analysis, 6-month PFS results were 27.1, 35, and 35.5 in all histologies, L, and A, respectively. When stratified by histology, we observed a better PFS favouring leiomyosarcoma versus other histologies (P 0.033). Treatment was well tolerated. Conclusions: Sorafenib appears to be a promising option in leiomyosarcoma patients. This finding warrants further evaluation in histology-driven trials.

AB - Introduction: We investigated the activity and safety of sorafenib, a multitargeted tyrosine-kinase inhibitor, in patients with advanced soft tissue sarcomas (STS). Patients and methods: An open-label nonrandomised multicentre phase II study was conducted in advanced STS patients pre-treated with anthracycline-based chemotherapy. Patients received sorafenib 400 mg twice daily for 28 days. The primary end point was the progression-free survival (PFS) rate at 6 months. Toxicity was assessed. Clinical outcomes were evaluated in all histologies and in leiomyosarcoma (L) and angiovascular sarcomas (A). Results: Between November 2006 and January 2010, 101 patients (36 L, 19 A, and 46 others) were enrolled; 76 patients per-protocol (PP) and 100 per intention-to-treat (ITT) were assessable for the primary end point. In the PP analysis, 11 (14.5) achieved partial response and 25 (32.9) stable disease; 6-month PFS rates were all histologies, 34.5; L, 38.4; and A, 56.3. In the ITT analysis, 6-month PFS results were 27.1, 35, and 35.5 in all histologies, L, and A, respectively. When stratified by histology, we observed a better PFS favouring leiomyosarcoma versus other histologies (P 0.033). Treatment was well tolerated. Conclusions: Sorafenib appears to be a promising option in leiomyosarcoma patients. This finding warrants further evaluation in histology-driven trials.

KW - Angiosarcoma

KW - Leiomyosarcoma

KW - Soft tissue sarcoma

KW - Sorafenib

KW - Vascular sarcoma

UR - http://www.scopus.com/inward/record.url?scp=84875632694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875632694&partnerID=8YFLogxK

U2 - 10.1093/annonc/mds607

DO - 10.1093/annonc/mds607

M3 - Article

C2 - 23230134

AN - SCOPUS:84875632694

VL - 24

SP - 1093

EP - 1098

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 4

M1 - mds607

ER -